Current report No. 1/2021 – Positive results of the phase II clinical trial on Celon Pharma’s DPI esketamine in bipolar treatment-resistant depression [03KET2018]

Date prepared: 01/08/2021, 7:23 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: In relation to the current report No. 45/2020 regarding the date for the presentation of results of the phase II clinical trial on esketamine-based DPI drug (Falkieri) in bipolar treatment-resistant depression,Read more »

Celon Pharma at Jefferies Virtual London Healthcare Conference

The Company’s representatives will take part in the largest pharmaceutical conference in Europe. Maciej Wieczorek, CEO of Celon Pharma S.A.: We are increasing the presence of our products abroad, building a strong position in the segment of inhalation products on the global pharmaceutical market; we are observing that companies from around the world are takingRead more »

The experts agree. The targeted drug against COVID currently developed by Celon Pharma might change the course of the disease.

Thanks to its cutting-edge, innovative approach, Celon Pharma fast-tracks confirmation of the efficacy of its treatment against SARS-COV-2. The new therapeutic approach designed by scientists at Celon Pharma combines the previously dispersed possible responses to the threat brought about by SARS-COV-2. That approach assumes shortening of the infection duration in affected patients and significant limitationRead more »

Celon Pharma at the GPW Innovation Day 2020

The GPW Innovation Day is a free-access conference during which representatives of companies operating in the field of new technologies, games or biotechnology meet with stock investors. This year, it will be held on-line on 23 and 24 June 2020. In the previous edition of the conference, the company presentations were participated by over 300Read more »